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Thank you ….
Syft Technologies Ltd.
CONCLUSION
Breath Analysis allows real-time monitoring of haemodialysis
efficacy.
Why?
Figure 5
Figure 8a
This may not seem very important I know.
But it is!
So, I’m bothering telling you so.
Dr Suess, The Sleep Book
Results
As seen in the image plot (Figure 4) generated from mass scan data obtained using the H3O+ precursor, masses 18, 36, and
54, all relating to ammonia and its water clusters, are good biomarkers of kidney function.
Changed analysis of density profiles of mass scan VOC pre and post haemodialysis showed masses from ammonia were the
predominant VOC (eg with H3O+ the ROC area was 0.983 for masses 18, 36, 54).
SIM scan monitoring of breath analysis during haemodialysis showed 3 patterns:
A.  Progressive decline (Figure 5);
B.  Increase at 1 hour then a progressive decline (Figure 6);
C.  An oscillatory pattern (Figure 7).
The patterns may reflect initial vs equilibrium breath analysis values.
The Ammonia Reduction Ratio (ARR) averaged 52.5 ± 5.5% (mean ± SEM) and Urea Reduction Ratio (URR ) averaged
63.4 ± 1.2%  taken over all studies (n=40).  ARR scatter was reduced in patients with more efficient dialysis (URR > 65%,
Figures 8a and 8b), when ARR was better correlated with decline in Plasma Creatinine (r= 0.578, p=0.024, n=15) than with
URR (r= 0.432, p=0.095, n=16).
Modelling a prior haemodialysis allowed prediction of timing of maximal decline in Breath Analysis with pattern A.  This
allows a prediction of optimal dialysis time (Figure 9).
Real time biomarkers which correlate with dialysis efficacy could provide clinicians
with a method for individual tayloring of dialysis dose.
Contemporary evidence supports the centuries old notion that expired breath and the headspaces above body fluids and products can serve
as biomarkers of organ function. Clinical responsiveness to alterations in clinical status or therapy is dependent upon timely, accurate,
relevant physiological data.  Current measures of urea and creatinine to assess renal urea reduction are invasive and cannot be repeated
frequently or reported quickly enough to define individual response to treatment in real time.  In contrast, breath analysis is minimally
invasive and can provide real time information about low molecular weight volatile organic compounds (VOCs) such as ammonia1,2.
Introduction
References
How are VOCs measured
from breath?
A number of spectrometric techniques
have been employed to measure trace
gases in complex mixtures such as
ambient air, breath and headspaces
above liquids.  Selected ion flow tube
mass spectrometry (SIFT-MS) real time
quantification of trace gases is based on
chemical inonisation and is capable of
measurements to low parts per billion
(ppbv) independent of the humidity of the
sample2.
METHODOLOGY
We examined the relationship between Breath Ammonia (BA),
Ammonia Reduction Ratio (ARR) and Urea Reduction Ration
(URR), in 40 dialysis treatments in 15 patients commencing
haemodialysis (HD).  Blood was collected just prior to
haemodialysis and 30 minutes after stopping.  Thirty minutes
prior to and after haemodialysis patients exhaled directly into
VOICE100 (SYFT Technologies Ltd., Christchurch, New
Zealand) and also inflated a Tedlar™ (polyvinyl fluoride) bag
(SKC Inc. Valley View Road, Eighty Four, PA USA) then and at
one hourly intervals during dialysis.  Haemodialysis was
performed on a Fresenius 4008B for 5 hours (Fresenius F8
polysulfone dialyser) (Figure 1).
VOCs were analysed by the chemical ionisation reactions of
precursor ions (NO+, O2+ and H3O+) with each VOC using
selected ion flow tube mass spectrometry (SIFT-MS) and a
VOICE100 (Syft).  The  VOICE100 was operated on in both
mass scan and selected ion monitoring (SIM) modes.
Mass scan analysis can be used to determine which masses
change the most between two chosen time points and thus act as
good biomarkers for dialysis efficacy.  A classification algorithm
using SIFT-MS data has been described elsewhere3. For each
mass, a mixed distribution made up of a kernel density and a
Dirac delta function is used to develop a probability density
profile from each time-point group using each sample’s
concentration value at that mass.
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Breath analysis study flow
Figure 1
Inclusion criteria
1.Patients receiving dialysis in the acute haemodialysis unit, Christchurch Hospital
2. >16 years of age
Exclusion criteria
1.No consent
2.Patients too ill
3.Patients receiving dialysis anywhere other than in the acute haemodialysis unit
4.<16 years of age
5.Patients unable to answer initial assessment questions
6.Patients with severe respiratory disease
Potential patients identified on Friday of the previous week
Consent discussion with patient at first session of the week.
Patient met at HD unit at 08:00. Complete initial screening sheet
To Syft rooms by wheelchair for 1 direct to machine and 1 bag breath sample
(PreBag)
Return to HD unit by wheelchair. Blood collected for: BUN – via lampson tube
Ammonia – on wet ice and to lab within 20 minutes of collection
Head space analysis – to Syft room
Remind patient of any dietry or other conditions
Bag breath collection at 1 hourly intervals from the time of dialysis starting. Bags
directly to the Syft room within 5 minutes of collection
At completion of dialysis blood collected as in stage 4
30 minutes after completion of dialysis stage 3 repeated (PostBag)
STAGE 1
STAGE 2
STAGE 3
STAGE 4
STAGE 5
STAGE 6
STAGE 7
Figure 2: Probability densities for a given mass Figure 3: Biomarker determination
For each mass (figure 2), the log-odds ratio is defined as the natural log of the probability of a group j classification divided by a group k
classification.  Biomarkers are found by determining which masses have log-odds density profiles with minimal area-of-overlap (AOO) (figure 3).
With significant inter-patient variability, intra-patient variability and small datasets, a paired analysis approach with normalisation was used to
pre-process the datasets. The mass scan analysis is interested simply in the magnitude of the relative change in VOC concentration between the
pre- and post-dialysis state, as thus the concentration data is normalised to half of the average of these two concentrations.  As such, the data is
bounded between [0 1], with values greater than 0.5 representing a decrease in concentration over the course of the dialysis treatment, and values
less than 0.5 representing an increase in concentration.  Biomarkers are displayed visually on an image plot using the difference between the pre-
and post-dialysis groups. Good biomarkers are recognised as those masses with a narrow distribution centered far from the increase/decrease
interface.   These can then be selected for Selected Ion Monitoring (SIM).
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